· SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA). Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol "SNWV".
· The combined company expects to receive approximately $13.0 million of gross proceeds at closing, including $12.0 million from non-redeeming holders of SEPA's Class A common stock and other PIPE investors, and $1.0 million from the SPAC sponsor converting a loan into equity on the same terms as the PIPE. Approximately $8.5 million of capital has already been committed.
· This funding is expected to be anchored by investors affiliated with Sweat Equity Partners and Mercury Life Sciences. The Company plans to solicit further participation from SANUWAVE's existing investor base, other institutions and strategic partners.
· SANUWAVE has two FDA approved medical devices in the wound care space. Its lead product, the UltraMIST ("UM") system, has nationwide schedule 1 reimbursement and is used by many top medical centers, including the Mayo Clinic. SANUWAVE has over 550 UM systems in active use and generated 59% of its Q2 2023 revenue from consumable sales of single use applicators.
· The proposed business combination values the combined company at a pro forma enterprise value of $127.5 million.
· The transaction is expected to close in the fourth quarter of 2023, subject to the satisfaction of the agreed upon closing conditions.
EDEN PRAIRIE, MN and HOUSTON, TX, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV) ("SANUWAVE" or the "Company"), a leading provider of next-generation FDA approved wound care products, today announced a business combination with SEP Acquisition Corp. (Nasdaq: SEPA) ("SEPA"), a publicly listed special purpose acquisition company. The transaction is expected to create a Nasdaq-listed company focused on the use of directed energy to improve healing in the $45 billion U.S. wound care market.
Upon completion of the proposed transaction, the combined company is expected to operate under the SANUWAVE name and will be listed on the Nasdaq Capital Market under the symbol "SNWV". The proposed transaction values the combined company at an enterprise value of $127.5 million. SANUWAVE investors are anticipated to have an approximately 69.6% equity ownership in the new entity, assuming the combined company receives approximately $13.0 million of gross proceeds at closing, including $12.0 million from non-redeeming holders of SEPA's Class A common stock and other PIPE investors, and $1.0 million from the SPAC sponsor converting a loan into equity on the same terms as the PIPE. Approximately $8.5 million of capital has already been committed, including $7.0 million of shares of SEPA's Class A common stock held by investors affiliated with Sweat Equity Partners and Mercury Life Sciences who have agreed to enter into voting and non-redemption agreements.
"I am pleased to announce this proposed transaction to the SANUWAVE and SEPA stockholders," said SANUWAVE CEO Morgan Frank. "SEPA is a strong, value-add partner, and this transaction will allow SANUWAVE to simplify its capital structure and gain a listing on the Nasdaq Capital Market while funding the Company for the exciting growth ahead. This is the next step in putting the Company on sound footing that will allow us to focus on rapid, profitable growth and to garner an equity valuation commensurate with our performance."
"We are excited to partner with SANUWAVE on a combination of our companies," said SEPA CEO Andrew White. "We believe this transaction is a 1+1=3 equation where new capabilities are created and opportunities opened. Sweat Equity Partners, together with Mercury Life Sciences, have a broad investor base, with long track records of success in the medical device and healthcare sectors, and we've already begun working with SANUWAVE to open new distribution opportunities and markets. We believe very strongly in this Company and the UltraMIST product and look forward to being a part of SANUWAVE's future success."
About SANUWAVE
SANUWAVE is a rapidly growing commercial stage medical device company in the $45 billion U.S. wound care space. It has two FDA approved products and its lead product, UltraMIST, has nationwide schedule 1 reimbursement from CMS (the Centers for Medicare & Medicaid Services, a part of the Department of Health and Human Services). The Company believes that wound care is undergoing a major change to evidence-based medicine and that reimbursement is being restructured around efficacy and cost effectiveness. To succeed, a product must align the needs of patients, physicians, and payors, and the Company believes that this favors SANUWAVE's directed energy products and that this is apparent in reimbursement rate trends. The Company has a strong IP portfolio with over 165 patents, and an attractive financial profile with high gross margins (for example, during the three months ended June 30, 2023 the Company's gross margin was 74%) and significant recurring revenue from consumables (for example, 59% of the Company's revenues in Q2 2023 were from UltraMist applicator sales). The Company anticipates positive adjusted EBITDA in Q4 2023 as the product manufacturing ramp commences and expects meaningful growth acceleration and profitability over the next several years.
The UltraMIST system, which currently constitutes over 90% of the Company's revenue, is a low frequency, non-contact ultrasound system that delivers energy through a fluid mist. The system never touches the wound and is pain free. This system promotes wound healing below the surface by modulating cell membranes to drive increased blood flow and capillary formation and enhances macrophage mediate VEGF and PDGF release to enhance removal of damaged tissues by neutrophils. The system also reduces pro inflammatory cytokines and kills bacteria and biofilms by lysing cell walls. The system is highly portable (weighing only 7 pounds) and fits with the "care to the edge" movement of shifting treatment away from hospitals and toward doctor's offices, nursing homes, assisted living facilities, and patient homes. Treatments take 3 to 20 minutes (average of 6 minutes) and can be performed by a nurse or physical therapist. The efficacy of the UltraMIST system is supported by numerous clinical studies performed at top medical institutions.
The Company has been operating under significant capacity constraints for the production of UltraMIST systems and anticipates a significant step function in Q4 2023 and Q1 2024, which the Company expects will allow for engagement with larger customers with deeper ordering potential. SANUWAVE anticipates being able to produce approximately two to three times more UltraMISTs in 2024 as in 2023. Owing to better pricing and higher usage rates, the Company is seeing new customers added that have twice or more the dollar value of consumables use of its existing customer base, and therefore plans to increase its capacity to produce consumables by approximately four times over the next 12 to 18 months to accommodate additional demand for procedures.
The Company's goal is to show accelerating, profitable growth in 2024 and believes that the SEPA transaction represents the next step in being able to focus on building this business and transforming the wound care space.
About SEPA
Sweat Equity Partners LP and Mercury Fund, including Mercury Life Sciences, are the co-sponsors of SEP Acquisition Corp. Sweat Equity Partners is a family office led by Andrew White with investments in SaaS, MedTech, CleanTech, PropTech and Domestic Energy segments. Mercury Life Sciences, a division of Mercury Fund, is a venture firm and studio dedicated to advancing innovation and breakthroughs in the field of life sciences, investing in early-stage biotech, pharma, medtech, and digital health companies. Over the past 18 years, Mercury Life Sciences has investments and/or exits in over a dozen life science companies. For more information, please see and .
Transaction Summary
The business combination values the combined company at a $127.5 million pro forma enterprise value. The combined company expects to receive approximately $13.0 million of gross proceeds, including $12.0 million from non-redeeming holders of SEPA's Class A common stock and other PIPE investors, and $1.0 million from the SPAC sponsor converting a loan into equity on the same terms as the PIPE. Approximately $8.5 million of capital has already been committed. The net proceeds of this transaction will be used to fund general corporate purposes. This offering is expected to be anchored by investors affiliated with Sweat Equity Partners and Mercury Life Sciences. Assuming $13.0 million in gross investment proceeds and the closing of the business combination, existing SANUWAVE shareholders will own approximately 69.62% of the combined company.
Subject to stockholder approval, all of SEPA's shares of Class B common stock are to be exchanged for shares of Class A common stock at a ratio of one share of Class B common stock for 0.277 shares of Class A common stock. Furthermore, as a condition to closing, all of SEPA's warrants, both public and private, must be exchanged at the same ratio for shares in the combined company, which will require stockholder and warrant holder approval. If approved by warrant holders, the publicly traded warrants will be valued at $0.50 per warrant and exchanged for shares of SEPA's Class A common stock at closing, comprising a total of 450,336 shares of Class A common stock. In total, SEPA's public warrant holders are expected to own approximately 4.0% of the pro forma combined company at closing. Prior to closing, and as a condition to closing, SANUWAVE is required to obtain the approval of the holders of 80.0% of its outstanding convertible promissory notes and warrants to convert such securities into shares of SANUWAVE common stock immediately prior to the closing with the goal of creating a simpler capital structure.
The boards of SANUWAVE and SEPA have unanimously approved the proposed business combination, which is expected to be completed in fourth quarter of 2023 subject to, among other things, approval by SEPA's stockholders, approval by SANUWAVE's stockholders, SANUWAVE's ability to obtain the approval of the holders of 80.0% of its outstanding convertible promissory notes and warrants to convert such securities into shares of SANUWAVE common stock immediately prior to the closing, and SEPA's ability to have at least $12.0 million at closing from proceeds of its Class A common stock that has not been redeemed and a PIPE transaction.
Faegre Drinker Biddle & Reath LLP served as legal advisor to SANUWAVE. ValueScope Inc. and Baker Donelson, Bearman, Caldwell & Berkowitz, PC served as financial and legal advisors, respectively, to SEPA.
Additional information about the proposed transaction, including a copy of the business combination agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by SEPA and SANUWAVE today with the Securities and Exchange Commission and will be available at www.sec.gov.
Conference Call Information
A business update will occur via conference call on August 24, 2023 at 8:30 a.m. EDT.
Telephone access is available by dialing the following numbers:
Conference ID: 13740784
Telephone access to the call will be available by dialing the following numbers:
Participant Listening: 1-877-407-0784 or 1-201-689-8560
OR click the Call me link for instant telephone access to the event.
A replay will be made available through September 7, 2023:
Replay Dial-In: 1-844-512-2921 or 1-412-317-6671
Access ID: 13740784
Forward-Looking Statements
This press release may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. SEPA's and SANUWAVE's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements may include, without limitation, the satisfaction of the closing conditions to the transactions described above (the "Transactions") and the timing of the closing of the Transactions. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of SEPA and SANUWAVE, and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (2) the inability to consummate the Transactions, including due to any failure to obtain approval of the stockholders of SEPA or SANUWAVE, or the other conditions to the closing in the merger agreement, such as the requirements that (i) SANUWAVE obtain the approval of the holders of 80% of its outstanding convertible promissory notes and warrants to convert such securities into shares of SANUWAVE's common stock immediately prior to the closing and (ii) SEPA shall have at least $12.0 million at closing resulting from proceeds of (a) SEPA's Class A common stock that has not been redeemed and (b) a private placement; (3) delays in obtaining or the inability to obtain any necessary regulatory approvals required to complete the Transactions; (4) the inability to obtain or maintain the listing of SEPA's securities on Nasdaq following the Transactions; (5) costs related to the Transactions; (6) changes in applicable laws or regulations; (7) the possibility that SEPA or SANUWAVE may be adversely affected by other economic, business, and/or competitive factors; and (8) other risks and uncertainties to be identified in the registration statement/proxy statement (when available) relating to the Transactions, including those under "Risk Factors" therein, and in other filings with the SEC made by SEPA and SANUWAVE. SEPA and SANUWAVE caution that the foregoing list of factors is not exclusive, and caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither SEPA nor SANUWAVE undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law.
Readers are referred to the most recent reports filed with the SEC by SEPA and SANUWAVE. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and neither SEPA nor SANUWAVE undertakes any obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Important Information About the Transactions and Where to Find It
SEPA and SANUWAVE will file relevant materials with the Securities and Exchange Commission (the "SEC"), including a Form S-4 registration statement to be filed by SEPA, which will include a prospectus with respect to SEPA's securities to be issued in connection with the proposed Merger and a proxy statement with respect to SEPA's and SANUWAVE's stockholder meetings at which SEPA's and SANUWAVE's stockholders will be asked to vote on the proposed merger and related matters. SEPA'S and SANUWAVE'S STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ, WHEN AVAILABLE, THE FORM S-4 AND THE AMENDMENTS THERETO AND OTHER INFORMATION FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTIONS, AS THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT SEPA, SANUWAVE, AND THE TRANSACTIONS. When available, the proxy statement contained in the Form S-4 and other relevant materials for the Transactions will be mailed to stockholders of SEPA and SANUWAVE as of a record date to be established for voting on the proposed merger and related matters. The preliminary Form S-4 registration statement and preliminary proxy statement, the final Form S-4 registration statement and definitive proxy statement and other relevant materials in connection with the Transactions (when they become available), and any other documents filed by SEPA and SANUWAVE with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov). SEPA's stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to SEPA at 3737 Buffalo Speedway, Suite 1750 Houston, Texas 77098. SANUWAVE's stockholders will be able to obtain a copy of such documents, without charge, by directing a request to SANUWAVE at 11495 Valley View Road, Eden Prairie, Minnesota 55344.
Participants in Solicitations
SEPA and SANUWAVE and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of SEPA and SANUWAVE, respectively, in respect of the proposed business combination. SEPA and SANUWAVE stockholders and other interested persons may obtain more detailed information regarding the names and interests in the Transactions of SEPA's and SANUWAVE's directors and executive officers in SEPA's and SANUWAVE's filings with the SEC, including when filed, the Form S-4 registration statement and the proxy statement. These documents can be obtained free of charge from the sources indicated above.
Disclaimer
This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities pursuant to the proposed Transactions or otherwise, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
· SANUWAVE Health Inc.(OTCQB:SNWV)已與SEP收購公司(納斯達克股票代碼:SEPA)簽訂了最終合併協議。收盤後,合併後的公司預計將在納斯達克資本市場上市,股票代碼爲 “SNWV”。
· 合併後的公司預計在收盤時將獲得約1300萬美元的總收益,其中包括來自SEPA的A類普通股的非贖回持有人和其他PIPE投資者的1200萬美元,以及來自SPAC發起人的100萬美元,其條件與PIPE相同,將貸款轉換爲股權。已經投入了大約850萬美元的資本。
· 預計這筆資金將由隸屬於Sweat Equity Partners和Mercury Life Sciences的投資者支持。該公司計劃邀請SANUWAVE現有的投資者羣、其他機構和戰略合作伙伴進一步參與。
· SANUWAVE 在傷口護理領域有兩款經美國食品藥品管理局批准的醫療設備。其主要產品UltraMist(“UM”)系統在全國範圍內報銷計劃1,被包括梅奧診所在內的許多頂級醫療中心使用。SANUWAVE有550多個UM系統在積極使用,其2023年第二季度收入的59%來自一次性塗抹器的消耗品銷售。
· 擬議的業務合併估值合併後的公司預計企業價值爲127,500,000美元。
· 該交易預計將於2023年第四季度完成,前提是商定的成交條件是否得到滿足。
明尼蘇達州伊甸草原和德克薩斯州休斯頓,2023 年 8 月 23 日(GLOBE NEWSWIRE)— 通過 NewMediaWir — 美國食品藥品管理局批准的下一代傷口護理產品的領先供應商SANUWAVE Health, Inc.(OTCQB:SNWV)(“SANUWAVE” 或 “公司”)今天宣佈與上市的特殊目的收購公司SEP收購公司(納斯達克股票代碼:SEPA)(“SEPA”)進行業務合併。預計該交易將創建一家在納斯達克上市的公司,專注於使用定向能來改善價值4500億美元的美國傷口護理市場的癒合。
擬議交易完成後,合併後的公司預計將以SANUWAVE的名義運營,並將在納斯達克資本市場上市,代碼爲 “SNWV”。擬議的交易估值合併後的公司的企業價值爲127,500,000美元。假設合併後的公司在收盤時獲得約1300萬美元的總收益,其中包括來自SEPAA的A類普通股的非贖回持有人和其他PIPE投資者的1200萬美元,以及SPAC發起人按與PIPE相同的條件將貸款轉換爲股權的100萬美元,預計SANUWAVE投資者將擁有新實體約69.6%的股權。已經承諾了約850萬美元的資本,其中包括與Sweat Equity Partners和Mercury Life Sciences有關聯的投資者持有的700萬美元SEPA的A類普通股,他們已同意簽訂投票和不贖回協議。
SANUWAVE首席執行官摩根·弗蘭克表示:“我很高興向SANUWAVE和SEPA的股東宣佈這項擬議的交易。”“SEPA是一個強大的增值合作伙伴,這筆交易將使SANUWAVE能夠簡化其資本結構,在納斯達克資本市場上市,同時爲公司未來的激動人心的增長提供資金。這是使公司站穩腳跟的下一步,這將使我們能夠專注於快速、盈利的增長,並獲得與我們的業績相稱的股票估值。”
SEPA首席執行官安德魯·懷特說:“我們很高興能與SANUWAVE合作合併我們的公司。”“我們認爲這筆交易是一個1+1=3的方程式,在這個方程式中,創造了新的能力,開闢了機會。Sweat Equity Partners和Mercury Life Sciences擁有廣泛的投資者基礎,在醫療器械和醫療保健領域有着悠久的成功記錄,我們已經開始與SANUWAVE合作,開闢新的分銷機會和市場。我們非常相信這家公司和UltraMist產品,並期待成爲SANUWAVE未來成功的一部分。”
關於 SANUWAVE
SANUWAVE是一家在價值4500萬美元的美國傷口護理領域快速發展的商業階段醫療器械公司。它有兩款經美國食品藥品管理局批准的產品,其主要產品UltraMist已獲得CMS(衛生與公共服務部下屬的醫療保險和醫療補助服務中心)的全國附表1報銷。該公司認爲,傷口護理正在向循證醫學發生重大變化,報銷正在圍繞療效和成本效益進行重組。要取得成功,產品必須符合患者、醫生和付款人的需求,該公司認爲這有利於SANUWAVE的定向能量產品,這在報銷率趨勢中顯而易見。公司擁有強大的知識產權組合,擁有超過165項專利,財務狀況極具吸引力,毛利率高(例如,在截至2023年6月30日的三個月中,公司的毛利率爲74%),消耗品經常性收入可觀(例如,公司2023年第二季度收入中有59%來自UltraMist塗抹器的銷售)。該公司預計,隨着產品製造業的開始,2023年第四季度調整後的息稅折舊攤銷前利潤將爲正數,並預計未來幾年將有意義的增長加速和盈利。
UltraMist系統目前佔公司收入的90%以上,它是一種低頻、非接觸式超聲系統,可通過液霧輸送能量。該系統從不接觸傷口,而且無疼痛。該系統通過調節細胞膜來推動血液流動和毛細血管形成的增加,促進表面以下的傷口癒合,並增強巨噬細胞介導的血管內皮生長因子和PDGF釋放,從而增強中性粒細胞對受損組織的去除。該系統還可以減少促炎細胞因子,並通過裂解細胞壁來殺死細菌和生物膜。該系統具有高度的便攜性(重量僅爲7磅),適合將治療從醫院轉移到醫生辦公室、療養院、輔助生活設施和患者住所的 “邊緣護理” 運動。治療需要 3 到 20 分鐘(平均 6 分鐘),可由護士或物理治療師進行。UltraMist 系統的功效得到了頂級醫療機構開展的大量臨床研究的支持。
該公司在UltraMist系統的生產方面一直受到嚴重的產能限制,預計2023年第四季度和2024年第一季度將實現重要的階梯職能,該公司預計這將允許與具有更大訂購潛力的較大客戶互動。SANUWAVE預計,到2024年,UltraMist的產量將是2023年的兩到三倍。由於更優惠的價格和更高的使用率,該公司正在增加新的客戶,其消耗品的美元價值是其現有客戶羣的兩倍或更多,因此計劃在未來12至18個月內將其消耗品生產能力提高約四倍,以滿足對手術的額外需求。
該公司的目標是在2024年實現加速的盈利增長,並認爲SEPA的交易是能夠專注於建立該業務和改變傷口護理領域的下一步。
關於 SEPA
Sweat Equity Partners LP和Mercury Fund,包括水星生命科學,是SEP收購公司的共同贊助商。Sweat Equity Partners是一家由安德魯·懷特領導的家族辦公室,投資於SaaS、醫療科技、清潔科技、房地產科技和國內能源領域。Mercury Life Sciences是Mercury Fund旗下的一家風險投資公司和工作室,致力於推動生命科學領域的創新和突破,投資早期的生物技術、製藥、醫療技術和數字健康公司。在過去的18年中,Mercury Life Sciences對十幾家生命科學公司進行了投資和/或退出。欲了解更多信息,請參閱 和。
交易摘要
合併後的公司估值爲127,500,000美元,預計企業價值爲127,500,000美元。合併後的公司預計將獲得約1300萬美元的總收益,其中包括來自SEPA的A類普通股的非贖回持有人和其他PIPE投資者的1200萬美元,以及來自SPAC發起人的100萬美元,其條件與PIPE相同,將貸款轉換爲股權。已經投入了大約850萬美元的資本。本次交易的淨收益將用於爲一般公司用途提供資金。預計此次發行將由與Sweat Equity Partners和Mercury Life Sciences相關的投資者主持假設投資收益總額爲1300萬美元並完成業務合併,那麼現有的SANUWAVE股東將擁有合併後公司約69.62%的股份。
經股東批准,SEPA的所有B類普通股都將按一股B類普通股兌0.277股A類普通股的比率兌換成A類普通股。此外,作爲收盤的條件,SEPA的所有認股權證,無論是公開的還是私有的,都必須以相同的比例兌換合併後的公司的股份,這將需要股東和認股權證持有人的批准。如果獲得認股權證持有人的批准,上市認股權證的價值將爲每份認股權證0.50美元,並在收盤時兌換成SEPA的A類普通股,共包括450,336股A類普通股。總的來說,SEPA的公開認股權證持有人預計將在收盤時擁有合併後公司約4.0%的股份。在收盤之前,作爲收盤的條件,SANUWAVE必須獲得其80.0%的未償還可轉換本票和認股權證持有人的批准,才能在收盤前立即將此類證券轉換爲SANUWAVE普通股,目的是建立更簡單的資本結構。
SANUWAVE和SEPA的董事會一致批准了擬議的業務合併,該合併預計將於2023年第四季度完成,但須獲得SANUWAVE股東的批准,SANUWAVE股東的批准,以及SANUWAVE能否在收盤前獲得其80.0%的未償還可轉換本票和認股權證持有人批准將此類證券轉換爲SANUWAVE普通股,以及SEPA有能力在收盤時從其A類收益中獲得至少1200萬美元尚未贖回的普通股和PIPE交易。
Faegre Drinker Biddle & Reath LLP 曾擔任 SANUWAVE 的法律顧問。ValueScope Inc.和貝克·多納爾森、Bearman、Caldwell & Berkowitz、PC 分別擔任國家環保局的財務和法律顧問。
有關擬議交易的更多信息,包括業務合併協議的副本和投資者演示文稿,將在SEPA和SANUWAVE今天向美國證券交易委員會提交的8-K表格最新報告中提供,並將在以下網址公佈 www.sec.gov。
電話會議信息
業務最新情況將於美國東部時間2023年8月24日上午 8:30 通過電話會議發佈。
撥打以下號碼即可接聽電話:
會議編號:13740784
撥打以下號碼即可通過電話接聽電話:
參與者聽力:1-877-407-0784 或 1-201-689-8560
或者單擊 “給我打電話” 鏈接,即時通過電話訪問活動。
重播將在2023年9月7日之前上線:
重播撥入:1-844-512-2921 或 1-412-317-6671
訪問ID:13740784
前瞻性陳述
本新聞稿可能包含1995年《私人證券訴訟改革法》“安全港” 條款所指的 “前瞻性陳述”。SEPA和SANUWAVE的實際業績可能與他們的預期、估計和預測不同,因此,您不應依賴這些前瞻性陳述作爲對未來事件的預測。諸如” 之類的詞期望,””估計,””項目,””預算,””預測,””預測,””打算,””計劃,””可能,””將,””可以,””應該,””相信,””預言,””潛力,””可能“和”繼續,” 類似的表述旨在識別此類前瞻性陳述。這些前瞻性陳述可能包括但不限於滿足上述交易(“交易”)的成交條件以及交易的完成時間。這些前瞻性陳述涉及重大風險和不確定性,可能導致實際結果與預期結果存在重大差異。這些因素中的大多數都超出了SEPA和SANUWAVE的控制範圍,因此很難預測。可能導致此類差異的因素包括但不限於:(1)發生任何可能導致合併協議終止的事件、變更或其他情況;(2)無法完成交易,包括由於未能獲得SEPA或SANUWAVE股東的批准,或者合併協議中的其他條件,例如(i)SANUWAVE獲得合併協議的要求批准其80%的未償還可轉換本票和認股權證的持有人將其兌換證券在收盤前夕轉換爲SANUWAVE普通股以及 (ii) SEPA在收盤時應有至少1200萬美元的收益,來自 (a) SEPA尚未贖回的A類普通股以及 (b) 私募的收益;(3) 延遲獲得或無法獲得完成交易所需的任何必要的監管部門批准;(4) 無法獲得或維持SEPA的上市交易後在納斯達克上市的證券;(5)與交易相關的成本;(6)適用法律的變化或法規;(7)SEPA或SANUWAVE可能受到其他經濟、商業和/或競爭因素的不利影響;(8)與交易相關的註冊聲明/委託書(如果有)中需要確定的其他風險和不確定性,包括其中的 “風險因素” 下的風險和不確定性,以及SEPA和SANUWAVE向美國證券交易委員會提交的其他文件。SEPA和SANUWAVE警告說,上述因素清單並不是排他性的,並提醒讀者不要過分依賴任何前瞻性陳述,這些陳述僅代表截至發表之日。SEPA和SANUWAVE均不承諾或承諾公開發布任何前瞻性陳述的任何更新或修訂,以反映其預期的任何變化或任何此類聲明所依據的事件、條件或情況的任何變化,但須遵守適用法律。
讀者可以參考SEPA和SANUWAVE向美國證券交易委員會提交的最新報告。提醒讀者不要過分依賴任何前瞻性陳述,這些陳述僅代表截至發表之日,SEPA和SANUWAVE均不承擔任何更新或修改前瞻性陳述的義務,無論是由於新信息、未來事件還是其他原因。
有關交易的重要信息以及在哪裏可以找到它
SEPA和SANUWAVE將向美國證券交易委員會(“SEC”)提交相關材料,包括SEPA將提交的S-4表格註冊聲明,其中將包括與擬議合併有關的SEPA證券的招股說明書,以及關於SEPA和SANUWAVE股東會議的委託書,SEPA和SANUWAVE的股東大會將要求SEPA和SANUWAVE的股東大會進行投票擬議的合併及相關事項。建議SEPA和SANUWAVE的股東和其他利益相關人員閱讀S-4表格及其修正案以及向美國證券交易委員會提交的與交易有關的其他信息,因爲這些材料將包含有關SEPA、SANUWAVE和交易的重要信息。S-4表格中包含的委託書和其他交易相關材料將在記錄日期之前郵寄給SEPA和SANUWAVE的股東,以就擬議的合併和相關事項進行表決。初步的S-4表格註冊聲明和初步委託書、最終的S-4表格註冊聲明和最終委託書以及與交易有關的其他相關材料(當它們可用時),以及SEPA和SANUWAVE向美國證券交易委員會提交的任何其他文件,都可以在美國證券交易委員會的網站上免費獲得(www.sec.gov)。SEPA的股東也可以免費獲得此類文件的副本,方法是向SEPA提出申請,地址是德克薩斯州休斯敦1750號套房77098的布法羅賽車場3737號。SANUWAVE的股東將能夠免費獲得此類文件的副本,方法是向位於明尼蘇達州伊甸草原山谷景路11495號的SANUWAVE提交申請,55344。
招標參與者
SEPA和SANUWAVE及其各自的董事、執行官和員工以及其他人員可能被視爲分別就擬議的業務合併向SEPA和SANUWAVE的股東征集代理人的參與者。SEPA和SANUWAVE的股東以及其他利益相關者可以在SEPA和SANUWAVE向美國證券交易委員會提交的文件中獲得有關SEPA和SANUWAVE董事和執行官在交易中的姓名和利益的更多詳細信息,包括提交時的S-4表格註冊聲明和委託書。這些文件可以從上述來源免費獲得。
免責聲明
本通信不應構成就任何證券或擬議的業務合併徵求代理人、同意或授權。本通信不應構成出售要約或根據擬議交易或其他方式招標購買任何證券的要約,也不得在任何此類司法管轄區的證券法進行註冊或獲得資格之前,在任何該要約、招標或出售爲非法的司法管轄區進行任何證券出售。除非通過符合經修訂的1933年《證券法》第10條要求的招股說明書,否則不得發行證券。